Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
61 hedge funds and large institutions have $172M invested in Stemline Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 15 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
5% more capital invested
Capital invested by funds: $163M → $172M (+$8.32M)
12% less funds holding
Funds holding: 69 → 61 (-8)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
+$19.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$9.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.74M |
| 5 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.16M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$7.55M |
| 3 |
Jennison Associates
New York
|
-$2.69M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.85M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.33M |
STML Hedge Fund Activity: Q1 2014 in Review
61 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2014, worth a combined $172M — up 5.1% from $163M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of STML and 7 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 25 added.
The largest buyer was TimesSquare Capital Management, opening a new position worth an estimated $19.7M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.16M.
- 61 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2014, down from 69 in Q4 2013.
- Funds reported $172M of Stemline Therapeutics, Inc. stock for Q1 2014, up 5.1% quarter-over-quarter.
- 7 funds opened new Stemline Therapeutics, Inc. positions in Q1 2014 and 15 closed out, a net change of -8 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2014 was TimesSquare Capital Management, an estimated $19.7M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2014 was Baker Bros. Advisors, an estimated $8.16M sold.
Based on aggregated 13F filings for Q1 2014.